Sort   by:  
 Page size 
TranscriptomicsThe systematic shortening of 3’ UTRs has limited influence on the relative change in protein abundance in proliferating cells
Alternative polyadenylation is an important cellular mechanism that enables generation of mRNA isoforms that differ in their 3' untranslated regions (3' UTRs) and consequently in their susceptibility to miRNA and RNA binding protein mediated regulation. A dramatic change in polyadenylation site usa...
ORGANISM(S): Homo sapiens 
2014-09-25 | E-GEOD-54950 | biostudies-arrayexpress
ProteomicsProteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. Here, we ...
ORGANISM(S): Homo sapiens (Human) 
2021-12-17 | PXD021265 | Pride
Multiple myeloma Tmt Lc-ms Cdk6 
GenomicsTranscriptional regulation by H3K122 acetylation in the lateral surface of the histone octamer
We characterize the acetylation of H3K122 for the first time. Towards this we mapped the genomic distribution of H3K122Ac, identified the enzyme introducing H3K122Ac, and addressed the functional contribution H3K122Ac to transcription. We found that H3K122Ac is associated with chromatin marks and ge...
ORGANISM(S): Homo sapiens 
2013-02-14 | E-GEOD-35954 | biostudies-arrayexpress
ProteomicsThe histone modifier KANSL2 is an actionable biomarker for response to epigenetic modifiers in multiple myeloma
Epigenetic aberrations are key drivers of multiple myeloma (MM), yet targeted therapies exploiting epigenetic alterations have not been established. By integrating clinical and molecular MM patient data sets with an unbiased genetic in vivoscreen, we identified KAT8 regulatory NSL complex subunit 2 ...
ORGANISM(S): Homo sapiens (Human) 
2026-02-22 | PXD066205 | Pride
Histone acetylation Hdac inhibitors Kansl2 Bet inhibitors Biomarker Multiple myeloma 
UnknownTRPC1- and TRPC3-dependent Ca2+ signaling in mouse cortical astrocytes affects injury-evoked astrogliosis in vivo.
Not available
S-EPMC5526095 | biostudies-literature
ProteomicsSynergistic efficacy of combined SUMOylation and proteasome inhibition in multiple myeloma
Relapsed/refractory multiple myeloma (r/r MM) is a disease with often poor prognosis. Hyperactive SUMO signaling is involved in both cancer pathogenesis and cancer progression. A state of increased SUMOylation has been associated with aggressive cancer biology. Here, we found that r/r MM is characte...
ORGANISM(S): Homo sapiens (Human) 
2022-08-01 | PXD032316 | Pride
Proteasome inhibitor Myeloma Sumoylation inhibitor 
ProteomicsProteogenomic landscape of multiple myeloma
Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and hold...
ORGANISM(S): Homo sapiens (Human) 
2024-07-09 | PXD038437 | Pride
Multiple myeloma Proteogenomics Plasma cells Therapeutic targets Clinical proteomics Risk signatures Biomarkers 
ProteomicsAn oncogenic SUMO program restricts the targetable cancer immunopeptidome
A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandom...
ORGANISM(S): Homo sapiens (Human) 
2026-04-06 | PXD060641 | Pride
Human Sumo Immunopeptidome Mhc-i Antigen presentation Cancer immunotherapy Phosphoproteome 
ProteomicsA targetable co-dependence of PI3Kα/δ and SUMO signaling in aggressive pancreatic cancer
The phosphatidylinositol-3-kinase (PI3K) signaling pathway plays a critical role in the biology and aggressive course of pancreatic ductal adenocarcinoma (PDAC), yet pharmacological PI3K targeting has not resulted in meaningful clinical success. Through genetic and pharmacological screenings, we ide...
ORGANISM(S): Homo sapiens (Human) 
2026-02-22 | PXD059116 | Pride
Phsphorylation Immunogenic cell death Sumoylation Tmt Pancreatic cancer Human Combination therapy Pi3k 
ProteomicsProteogenomic landscape of multiple myeloma 
Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and hold...
ORGANISM(S): Homo sapiens (Human) 
2024-07-09 | PXD043580 | Pride
Ube2q1 Macs sorting Multiple myeloma 
Sort   by:  
 Page size